Reduced sphingosine kinase-1 and enhanced sphingosine 1-phosphate lyase expression demonstrate deregulated sphingosine 1-phosphate signaling in Alzheimer's disease

Acta Neuropathologica Communications

Volumn 2, Issue 1, 2014, Pages

  Ceccom, Johnatan ^a,b   Loukh, Najat ^a   Lauwers Cances, Valérie ^a   Touriol, Christian ^d   Nicaise, Yvan ^a   Gentil, Catherine ^a   Uro Coste, Emmanuelle ^a,d   Pitson, Stuart ^e   Maurage, Claude Alain ^f,g,h   Duyckaerts, Charles ⁱ   Cuvillier, Olivier ^b,c   Delisle, Marie Bernadette ^a,d  

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ PAUL SABATIER   (France)

^c INSTITUT DE PHARMACOLOGIE ET DE BIOLOGIE STRUCTURALE   (France)

^d CANCER RESEARCH CENTER OF TOULOUSE   (France)

^e CENTRE FOR CANCER BIOLOGY   (Australia)

^f JEAN PIERRE AUBERT RESEARCH CENTER   (France)

^g LILLE UNIVERSITY HOSPITAL   (France)

^h UNIV LILLE   (France)

ⁱ PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Alzheimer's disease; Beta amyloid; Neuropathology; Sphingolipids; Sphingosine 1 phosphate lyase; Sphingosine kinase 1

Indexed keywords

AMYLOID BETA PROTEIN; LYASE; PHOSPHOTRANSFERASE; SPHINGOSINE 1-PHOSPHATE LYASE (ALDOLASE); SPHINGOSINE KINASE;

AGED; ALZHEIMER DISEASE; BRAIN; FEMALE; GENE EXPRESSION REGULATION; HUMAN; MALE; METABOLISM; MIDDLE AGED; NERVE CELL; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; STATISTICS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALDEHYDE-LYASES; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BRAIN; FEMALE; GENE EXPRESSION REGULATION; HUMANS; MALE; MIDDLE AGED; NEURONS; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); SIGNAL TRANSDUCTION; STATISTICS AS TOPIC;

EID: 84902831529     PISSN: None     EISSN: 20515960     Source Type: Journal    
DOI: 10.1186/2051-5960-2-12     Document Type: Article

References (56)

1. Duyckaerts C, Delatour B, Potier MC: Classification and basic pathology of Alzheimer disease. Acta Neuropathol 2009, 118: 5-36.
2. Nelson PT, Alafuzoff I, Bigio EH, et al.: Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol 2012, 71: 362-381.
3. Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K: Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 2006, 112: 389-404.
4. Braak H, Braak E: Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991, 82: 239-259.
5. Thal DR, Rub U, Orantes M, Braak H: Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 2002, 58: 1791-1800.
6. Farooqui AA, Horrocks LA, Farooqui T: Interactions between neural membrane glycerophospholipid and sphingolipid mediators: a recipe for neural cell survival or suicide. J Neurosci Res 2007, 85: 1834-1850.
7. Hartmann T, Kuchenbecker J, Grimm MO: Alzheimer's disease: the lipid connection. J Neurochem 2007, 103(Suppl 1):159-170.
8. Marquer C, Devauges V, Cossec JC: Local cholesterol increase triggers amyloid precursor protein-Bace1 clustering in lipid rafts and rapid endocytosis. FASEB J 2011, 25: 1295-1305.
9. Yankner BA, Lu T, Loerch P: The aging brain. Annu Rev Pathol 2008, 3: 41-66.
10. Hannun YA, Obeid LM: Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol 2008, 9: 139-150.
11. Spiegel S, Milstien S: Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat Rev Mol Cell Biol 2003, 4: 397-407.
12. Cuvillier O: Sphingosine in apoptosis signaling. Biochim Biophys Acta 2002, 1585: 153-162.
13. Pitson SM: Regulation of sphingosine kinase and sphingolipid signaling. Trends Biochem Sci 2011, 36: 97-107.
14. Spiegel S, Cuvillier O, Edsall LC: Sphingosine-1-phosphate in cell growth and cell death. Ann N Y Acad Sci 1998, 845: 11-18.
15. Cuvillier O, Pirianov G, Kleuser B: Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. Nature 1996, 381: 800-803.
16. Rosen H, Gonzalez-Cabrera PJ, Sanna MG, Brown S: Sphingosine 1-phosphate receptor signaling. Annu Rev Biochem 2009, 78: 743-768.
17. Alvarez SE, Harikumar KB, Hait NC, et al.: Sphingosine-1-phosphate is a missing cofactor for the E3 ubiquitin ligase TRAF2. Nature 2010, 465: 1084-1088.
18. Hait NC, Allegood J, Maceyka M: Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate. Science 2009, 325: 1254-1257.
19. Cuvillier O: Downregulating sphingosine kinase-1 for cancer therapy. Expert Opin Ther Targets 2008, 12: 1009-1020.
20. Aguilar A, Saba JD: Truth and consequences of sphingosine-1-phosphate lyase. Adv Biol Regul 2012, 52: 17-30.
21. Brizuela L, Ader I, Mazerolles C, Bocquet M, Malavaud B, Cuvillier O: First evidence of sphingosine 1-phosphate lyase protein expression and activity downregulation in human neoplasm: implication for resistance to therapeutics in prostate cancer. Mol Cancer Ther 2012, 11: 1841-1851.
22. He X, Huang Y, Li B, Gong CX, Schuchman EH: Deregulation of sphingolipid metabolism in Alzheimer's disease. Neurobiol Aging 2010, 31: 398-408.
23. Rivera EJ, Goldin A, Fulmer N, Tavares R, Wands JR, de la Monte SM: Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine. J Alzheimers Dis 2005, 8: 247-268.
24. Mielke MM, Lyketsos CG: Alterations of the sphingolipid pathway in Alzheimer's disease: new biomarkers and treatment targets? Neuromolecular Med 2010, 12: 331-340.
25. Bandaru VV, Troncoso J, Det W: ApoE4 disrupts sterol and sphingolipid metabolism in Alzheimer's but not normal brain. Neurobiol Aging 2009, 30: 591-599.
26. Cutler RG, Kelly J, Storie K: Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. Proc Natl Acad Sci USA 2004, 101: 2070-2075.
27. Han X, MH D, McKeel DW Jr, Kelley J, Morris JC: Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer's disease: potential role in disease pathogenesis. J Neurochem 2002, 82: 809-818.
28. Katsel P, Li C, Haroutunian V: Gene expression alterations in the sphingolipid metabolism pathways during progression of dementia and Alzheimer's disease: a shift toward ceramide accumulation at the earliest recognizable stages of Alzheimer's disease? Neurochem Res 2007, 32: 845-856.
29. Pettegrew JW, Panchalingam K, Hamilton RL, McClure RJ: Brain membrane phospholipid alterations in Alzheimer's disease. Neurochem Res 2001, 26: 771-782.
30. Satoi H, Tomimoto H, Ohtani R, et al.: Astroglial expression of ceramide in Alzheimer's disease brains: a role during neuronal apoptosis. Neuroscience 2005, 130: 657-666.
31. Mielke MM, Bandaru VVR, Haughey NJ, Rabins PV, Lyketsos CG, Carlson MC: Serum sphingomyelins and ceramides are early predictors of memory impairment. Neurobiol Aging 2010, 31: 17-24.
32. Mielke MM, Haughey NJ, Bandaru VVR, et al.: Plasma ceramides are altered in mild cognitive impairment and predict cognitive decline and hippocampal volume loss. Alzheimers & Dementia 2010, 6: 378-385.
33. Gomez-Brouchet A, Pchejetski D, Let B: Critical role for sphingosine kinase-1 in regulating survival of neuroblastoma cells exposed to amyloid-beta peptide. Mol Pharmacol 2007, 72: 341-349.
34. Lee JT, Xu J, Lee JM, et al.: Amyloid-beta peptide induces oligodendrocyte death by activating the neutral sphingomyelinase-ceramide pathway. J Cell Biol 2004, 164: 123-131.
35. Puglielli L, Ellis BC, Saunders AJ, Kovacs DM: Ceramide stabilizes beta-site amyloid precursor protein-cleaving enzyme 1 and promotes amyloid beta-peptide biogenesis. J Biol Chem 2003, 278: 19777-19783.
36. Edsall LC, Cuvillier O, Twitty S, Spiegel S, Milstien S: Sphingosine kinase expression regulates apoptosis and caspase activation in PC12 cells. J Neurochem 2001, 76: 1573-1584.
37. Carro E, Torres-Aleman I: The role of insulin and insulin-like growth factor I in the molecular and cellular mechanisms underlying the pathology of Alzheimer's disease. Eur J Pharmacol 2004, 490: 127-133.
38. Flanders KC, Ren RF, Lippa CF: Transforming growth factor-betas in neurodegenerative disease. Prog Neurobiol 1998, 54: 71-85.
39. Tesseur I, Zou K, Esposito L, et al.: Deficiency in neuronal TGF-beta signaling promotes neurodegeneration and Alzheimer's pathology. J Clin Invest 2006, 116: 3060-3069.
40. Hemmati F, Dargahi L, Nasoohi S, et al.: Neurorestorative effect of FTY720 in a rat model of Alzheimer's disease: comparison with memantine. Behav Brain Res 2013, 252C: 415-421.
41. Montine TJ, Phelps CH, Beach TG, et al.: National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol 2012, 123: 1-11. 10.1007/s00401-011-0910-3
42. Pitson SM, Moretti PA, Zebol JR, et al.: Activation of sphingosine kinase 1 by ERK1/2-mediated phosphorylation. EMBO J 2003, 22: 5491-5500.
43. Duyckaerts C, Hauw JJ, Bastenaire F: Laminar distribution of neocortical senile plaques in senile dementia of the Alzheimer type. Acta Neuropathol 1986, 70: 249-256.
44. Tu YK, Gilthorpe MS: Revisiting the relation between change and initial value: a review and evaluation. Stat Med 2007, 26: 443-457. 10.1002/sim.2538
45. Musicco M, Adorni F, Di Santo S, et al.: Inverse occurrence of cancer and Alzheimer disease: a population-based incidence study. Neurology 2013, 81: 322-328.
46. Malaplate-Armand C, Florent-Bechard S, Youssef I, et al.: Soluble oligomers of amyloid-beta peptide induce neuronal apoptosis by activating a cPLA2-dependent sphingomyelinase-ceramide pathway. Neurobiol Dis 2006, 23: 178-189.
47. Takasugi N, Sasaki T, Suzuki K, et al.: BACE1 activity is modulated by cell-associated sphingosine-1-phosphate. J Neurosci 2011, 31: 6850-6857.
48. Gomez-Isla T, Price JL, McKeel DW Jr, Morris JC, Growdon JH, Hyman BT: Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J Neurosci 1996, 16: 4491-4500.
49. Colie S, Codogno P, Levade T, Andrieu-Abadie N: Regulation of cell death by sphingosine 1-phosphate lyase. Autophagy 2010, 6: 426-427.
50. Morgan AR, Turic D, Jehu L, et al.: Association studies of 23 positional/functional candidate genes on chromosome 10 in late-onset Alzheimer's disease. Am J Med Genet B Neuropsych Genet 2007, 144B: 762-770.
51. Kumar A, Byun HS, Bittman R, Saba JD: The sphingolipid degradation product trans-2-hexadecenal induces cytoskeletal reorganization and apoptosis in a JNK-dependent manner. Cell Signal 2011, 23: 1144-1152.
52. Alvarez SE, Milstien S, Spiegel S: Autocrine and paracrine roles of sphingosine-1-phosphate. Trends Endocrinol Metab 2007, 18: 300-307.
53. Carro E, Trejo JL, Gerber A: Therapeutic actions of insulin-like growth factor I on APP/PS2 mice with severe brain amyloidosis. Neurobiol Aging 2006, 27: 1250-1257.
54. Carro E, Trejo JL, Spuch C, Bohl D, Heard JM, Torres-Aleman I: Blockade of the insulin-like growth factor I receptor in the choroid plexus originates Alzheimer's-like neuropathology in rodents: new cues into the human disease? Neurobiol Aging 2006, 27: 1618-1631.
55. Zhao WQ, Lacor PN, Chen H, et al.: Insulin receptor dysfunction impairs cellular clearance of neurotoxic oligomeric a(beta}. J Biol Chem 2009, 284: 18742-18753.
56. Brinkmann V: Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacol Ther 2007, 115: 84-105.